Impact of SARS-CoV-2 Pandemic on Diagnosis of Prostate Cancer.

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY Urologia Internationalis Pub Date : 2024-10-03 DOI:10.1159/000541753

Immanuel A Oppolzer, Marco J Schnabel, Selma Hammer, Hannah Zilles, Maximilian Haas, Christopher Goßler, Maximilian R Müller, Maximilian Burger, Michael Gierth

{"title":"Impact of SARS-CoV-2 Pandemic on Diagnosis of Prostate Cancer.","authors":"Immanuel A Oppolzer, Marco J Schnabel, Selma Hammer, Hannah Zilles, Maximilian Haas, Christopher Goßler, Maximilian R Müller, Maximilian Burger, Michael Gierth","doi":"10.1159/000541753","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of this study was to prove if the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC).Methods: A monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2 pandemic and 14 months preceding it.Results: Nine hundred sixty-nine men prior (T0) and 1,343 during the pandemic (T1) were included. Mean age was 68.0 (SD 8.2). Median initial prostate-specific antigen was 8.1 ng/mL (T0) and 7.9 ng/mL (T1, p = 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p = 0.001), to staging (T0: 1.1 months vs. T1: 0.75 months, p = 0.707), and to therapy (T0: 3.0 months vs. T1: 2.0 months, p < 0.001) was shortened during the pandemic. Classified by d'Amico, a significant shift toward higher risk groups was seen (p = 0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3% to 8.9% (p = 0.433). Pathological staging showed pT3+ in 44.4% versus 44.7% (p = 0.565) and pN+ in 9.9% versus 9.6% (p = 0.899).Conclusion: Regarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2 pandemic.","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-9"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541753","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The aim of this study was to prove if the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC).

Methods: A monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2 pandemic and 14 months preceding it.

Results: Nine hundred sixty-nine men prior (T0) and 1,343 during the pandemic (T1) were included. Mean age was 68.0 (SD 8.2). Median initial prostate-specific antigen was 8.1 ng/mL (T0) and 7.9 ng/mL (T1, p = 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p = 0.001), to staging (T0: 1.1 months vs. T1: 0.75 months, p = 0.707), and to therapy (T0: 3.0 months vs. T1: 2.0 months, p < 0.001) was shortened during the pandemic. Classified by d'Amico, a significant shift toward higher risk groups was seen (p = 0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3% to 8.9% (p = 0.433). Pathological staging showed pT3+ in 44.4% versus 44.7% (p = 0.565) and pN+ in 9.9% versus 9.6% (p = 0.899).

Conclusion: Regarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2 pandemic.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

SARS-CoV-2大流行对前列腺癌诊断的影响。

引言本研究旨在证明 SARS-CoV-2 大流行是否导致了前列腺癌（PC）诊断和治疗的延误。方法在一所大学癌症中心进行了单中心回顾性分析。研究对象包括在 2019 年 1 月至 2021 年 12 月期间确诊的所有未经治疗的 PC 患者。观察时间涵盖 SARS-CoV-2 大流行期间的 22 个月和之前的 14 个月。结果纳入了969名之前（T0）和1343名大流行期间（T1）的男性患者。平均年龄为 68.0 (SD 8.2)。初始 PSA 中位数为 8.1 纳克/毫升（T0）和 7.9 纳克/毫升（T1，P= 0.288）。大流行期间，从活检到肿瘤检查（T0：1.3 个月 vs. T1：0.9 个月，p=0.001）、分期（T0：1.1 个月 vs. T1：0.75 个月，p=0.707）和治疗（T0：3.0 个月 vs. T1：2.0 个月，p<0.001）的时间都缩短了。按 d'Amico 分类，高危人群明显增加（p=0.024）。局部分期显示，局部晚期 PCs 的增加并不明显。转移性疾病从 10.3% 降至 8.9%（P=0.433）。病理分期显示，44.4%的患者为pT3+，44.7%的患者为pN+（p=0.565），9.9%的患者为pN+，9.6%的患者为pN+（p=0.899）。结论在 PC 的诊断和治疗方面，我们没有发现任何因 SARS-CoV-2 大流行而导致的延误。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Urologia Internationalis 医学-泌尿学与肾脏学

CiteScore

3.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.